Thrombospondin-1/CD47 Blockade following Ischemia-Reperfusion Injury Is Tissue Protective

Abstract

Therapies targeting the thrombospondin-1 receptor CD47 offer potential for increasing tissue survival in ischemia-reperfusion injuries. The ability to protect when given after ischemia-reperfusion injury enables a broader clinical applicability.